US 12,286,483 B2
Method of treating cancer using CD137 antibodies and PD-1 antagonists
Ugur Eskiocak, Somerville, MA (US); and Robert V. Tighe, III, North Reading, MA (US)
Assigned to Compass Therapeutics LLC, Cambridge, MA (US)
Filed by Compass Therapeutics LLC, Brighton, MA (US)
Filed on May 25, 2023, as Appl. No. 18/323,772.
Application 18/323,772 is a continuation of application No. 16/760,600, granted, now 11,718,679, previously published as PCT/US2018/058451, filed on Oct. 31, 2018.
Claims priority of provisional application 62/579,337, filed on Oct. 31, 2017.
Prior Publication US 2024/0002525 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/001111 (2018.08); A61K 39/001117 (2018.08); A61P 35/00 (2018.01); A61K 2039/507 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method for treating cancer in a subject, the method comprising: administering to the subject an effective amount of:
(i) an isolated agonistic monoclonal antibody that specifically binds to human CD137 with an affinity (KD) of about 30-100 nM, or that binds to an epitope on human CD137 comprising K114 of SEQ ID NO: 3, or both, or an antigen-binding fragment thereof; and
(ii) a PD-1 antagonist,
wherein the agonistic monoclonal antibody or antigen-binding fragment thereof is administered to the subject prior to administration of the PD-1 antagonist, thereby treating the subject,
and wherein the agonistic monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 129 or SEQ ID NO: 131 and a light chain comprising the amino acid sequence of SEQ ID NO: 6.